CO2022018426A2 - Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso - Google Patents

Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso

Info

Publication number
CO2022018426A2
CO2022018426A2 CONC2022/0018426A CO2022018426A CO2022018426A2 CO 2022018426 A2 CO2022018426 A2 CO 2022018426A2 CO 2022018426 A CO2022018426 A CO 2022018426A CO 2022018426 A2 CO2022018426 A2 CO 2022018426A2
Authority
CO
Colombia
Prior art keywords
neoantigen
complex
methods
antibodies targeting
classical hla
Prior art date
Application number
CONC2022/0018426A
Other languages
English (en)
Inventor
Jon Weidanz
Katherine Upchurch-Ange
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO2022018426A2 publication Critical patent/CO2022018426A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan anticuerpos que se unen selectivamente a un complejo que comprende un HLA–I no clásico (por ejemplo, HLA–E) y un neoantígeno que tiene dominios variables de la cadena pesada (VH), dominios variables de la cadena ligera (VL) y regiones determinantes de complementariedad (CDR) como se divulga en la presente, así como métodos y usos de estos.
CONC2022/0018426A 2020-06-01 2022-12-19 Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso CO2022018426A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032747P 2020-06-01 2020-06-01
US17/199,205 US11359023B2 (en) 2020-06-01 2021-03-11 Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
PCT/US2021/035290 WO2021247607A1 (en) 2020-06-01 2021-06-01 Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use

Publications (1)

Publication Number Publication Date
CO2022018426A2 true CO2022018426A2 (es) 2022-12-30

Family

ID=75495114

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0018426A CO2022018426A2 (es) 2020-06-01 2022-12-19 Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso

Country Status (19)

Country Link
US (4) US10981996B1 (es)
EP (1) EP4157882A4 (es)
JP (1) JP2023530036A (es)
KR (1) KR20230019468A (es)
CN (1) CN116367865A (es)
AR (1) AR122501A1 (es)
AU (1) AU2021284275A1 (es)
BR (1) BR112022024275A2 (es)
CA (1) CA3174090A1 (es)
CL (1) CL2022003336A1 (es)
CO (1) CO2022018426A2 (es)
CR (1) CR20220652A (es)
DO (1) DOP2022000268A (es)
EC (1) ECSP22097197A (es)
IL (1) IL298020A (es)
MX (1) MX2022015114A (es)
PE (1) PE20230306A1 (es)
TW (1) TW202235439A (es)
WO (1) WO2021247607A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107001A1 (en) * 2018-07-23 2020-01-30 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
WO2023196541A1 (en) * 2022-04-08 2023-10-12 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2998320B1 (en) 2011-04-19 2018-07-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CA2932288C (en) * 2013-12-17 2021-11-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN103773775B (zh) 2014-01-26 2015-11-18 江苏省农业科学院 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用
BR112016029860A2 (pt) 2014-06-20 2017-10-24 Abgenomics Int Inc conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
CN114478792A (zh) 2015-01-08 2022-05-13 根马布股份公司 针对cd3和cd20的双特异性抗体
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018140525A1 (en) 2017-01-24 2018-08-02 Abexxa Biologics, Inc. Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer
EP3755371A4 (en) 2018-02-23 2021-11-24 Abexxa Biologics, Inc. ANTI-CANCER TREATMENT COMBINED WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN
CA3107001A1 (en) 2018-07-23 2020-01-30 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Also Published As

Publication number Publication date
DOP2022000268A (es) 2023-01-15
EP4157882A4 (en) 2024-06-26
PE20230306A1 (es) 2023-02-13
US20210371532A1 (en) 2021-12-02
CR20220652A (es) 2023-07-03
JP2023530036A (ja) 2023-07-12
ECSP22097197A (es) 2023-02-28
KR20230019468A (ko) 2023-02-08
IL298020A (en) 2023-01-01
US20240026007A1 (en) 2024-01-25
AR122501A1 (es) 2022-09-14
EP4157882A1 (en) 2023-04-05
CN116367865A (zh) 2023-06-30
WO2021247607A1 (en) 2021-12-09
US11359023B2 (en) 2022-06-14
US10981996B1 (en) 2021-04-20
AU2021284275A1 (en) 2023-01-19
US20220332831A1 (en) 2022-10-20
CL2022003336A1 (es) 2023-06-23
CA3174090A1 (en) 2021-12-09
MX2022015114A (es) 2023-03-24
TW202235439A (zh) 2022-09-16
BR112022024275A2 (pt) 2023-05-02

Similar Documents

Publication Publication Date Title
CO2022018426A2 (es) Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso
ECSP22097203A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
AR122502A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
CO2022008407A2 (es) Anticuerpos específicos para cd47, pd–l1 y sus usos
CL2008003781A1 (es) Anticuerpo bivalente biespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un antigeno, y la cadena ligera y pesada de un anticuerpo que se une a un antigeno diferente, donde los dominios variables vl y vh estan cambiados el uno por el otro; metodo de preparacion; celula huesped; y composicion.
CL2008003779A1 (es) Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica.
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
PE20191031A1 (es) ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
CO2022013898A2 (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
PH12021550232A1 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
CO2023007097A2 (es) Anticuerpos multiespecíficos y combinaciones de anticuerpos
CO2023004381A2 (es) Anticuerpos cd1a y su uso
AR120093A1 (es) Anticuerpos anti-ceacam y usos de los mismos
BR112021020677A2 (pt) Anticorpos contra receptores de antígeno quimérico derivados de 4g7
PE20230986A1 (es) Anticuerpo que se une a vegf-a y ang2, y metodos de uso